MIRABEGRON
| Brand name | MYRBETRIQ GRANULES |
|---|---|
| Active ingredient | MIRABEGRON |
| Strength | 8MG/ML |
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | March 2021 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 10058536*PED | September 2036 | — |
| 10058536 | March 2036 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.